The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma (TIDE-asthma)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05421598
Recruitment Status : Active, not recruiting
First Posted : June 16, 2022
Last Update Posted : December 5, 2023
Sponsor:
Information provided by (Responsible Party):
Sanofi

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

This is a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.

The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma.

Study details include:

  • The study duration (per participant) will be up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study.
  • The randomized treatment duration will be up to approximately 60 weeks.
  • The scheduled number of visits will be 13.

Condition or disease Intervention/treatment Phase
Asthma Drug: Amlitelimab Drug: Placebo Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 446 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma
Actual Study Start Date : June 30, 2022
Estimated Primary Completion Date : October 4, 2024
Estimated Study Completion Date : March 21, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Amlitelimab dose level 1
Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 1 every 4 weeks (Q4W) until Week 20 (inclusive) and every 12 weeks (Q12W) starting from Week 24 and thereafter.
 Drug: Amlitelimab
Injection solution Subcutaneous injection
Experimental: Amlitelimab dose level 2
Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 2 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
 Drug: Amlitelimab
Injection solution Subcutaneous injection
Experimental: Amlitelimab dose level 3
Initial loading dose of amlitelimab on Day 1, followed by one injection of amlitelimab dose level 3 Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
 Drug: Amlitelimab
Injection solution Subcutaneous injection
Placebo Comparator: Placebo
Initial loading dose of amlitelimab matching placebo on Day 1, followed by one injection of amlitelimab matching placebo Q4W until Week 20 (inclusive) and Q12W starting from Week 24 and thereafter.
 Drug: Placebo
Injection solution Subcutaneous injection


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Annualized rate of severe exacerbation events over 48 weeks [ Time Frame: Baseline through Week 48 ]
    Severe exacerbation events are defined as: worsening of asthma requiring the use of systemic corticosteroids for ≥3 days or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.


Secondary Outcome Measures :
  1. Change from baseline in pre-bronchodilator (BD) FEV1 at Week 48 [ Time Frame: Baseline to Week 48 ]
    Change from baseline in pre-bronchodilator (BD) FEV1 at Week 48.

  2. Change from baseline in Asthma Control Questionnaire 5 (ACQ-5) score at Week 48 [ Time Frame: Baseline to Week 48 ]
    The ACQ-5 has five questions on the asthma symptoms. The score ranges from 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

  3. Change from baseline in Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ (S)) Self-Administered Score at Week 48 [ Time Frame: Baseline to Week 48 ]
    The AQLQ(S) is designed as a self-administered participant reported outcome to measure the functional impairments. The overall score is 1 to 7. Higher AQLQ scores indicate better health-related quality of life.

  4. Change from baseline in post-BD FEV1 at Week 48 [ Time Frame: Baseline to Week 48 ]
    Change from baseline in post-BD FEV1 at Week 48.

  5. The absolute change in the percent predicted FEV1 from baseline to Week 48 (pre-BD and post-BD) [ Time Frame: Baseline to Week 48 ]
    The absolute change in the percent predicted FEV1 from baseline to Week 48 (pre-BD and post-BD).

  6. Change from baseline in ACQ-5 score at Weeks 2, 4, 8, 12, 24, 36, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, and 60 ]
    The ACQ-5 has five questions on the asthma symptoms. The score ranges from 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control.

  7. Time to first severe exacerbation event [ Time Frame: Baseline through Week 48 ]
    Severe exacerbation events are defined as: worsening of asthma requiring the use of systemic corticosteroids for ≥3 days or, in the case of a stable maintenance regimen of oral corticosteroids for the treatment of asthma, a doubling of the dose for 3 or more days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.

  8. Change from baseline in pre-BD and post-BD FEV1 [ Time Frame: Baseline to Weeks 2, 4, 8, 12,16, 24, 36 and 60 ]
    Change from baseline in pre-BD and post-BD FEV1.

  9. Change from baseline in peak expiratory flow (PEF) and forced expiratory flow (FEF) 25-75% [ Time Frame: Baseline to Weeks 4, 12, 24, 36, 48 and 60 ]
    Change from baseline in peak expiratory flow (PEF) and forced expiratory flow (FEF) 25-75%.

  10. Change from baseline in forced vital capacity (FVC) [ Time Frame: Baseline to Weeks 4, 12, 24, 36, 48 and 60 ]
    Change from baseline in forced vital capacity (FVC).

  11. Change from baseline in FeNO at Weeks 2, 4, 8, 12, 16, 24, 36, 48 and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 16, 24, 36, 48 and 60 ]
    Change from baseline in FeNO at Weeks 2, 4, 8, 12, 16, 24, 36, 48 and 60.

  12. Annualized rate of loss of asthma control (LOAC) events during 48 weeks of treatment [ Time Frame: Baseline through Week 48 ]

    LOAC events are defined by one or several of the following criteria:

    A 30% or greater reduction from baseline in morning PEF on 2 consecutive days.

    ≥6 additional reliever puffs of short-acting beta-agonists (SABA) OR ≥4 additional puffs of low-dose inhaled corticosteroid (ICS)/formoterol in a 24-hour period (compared to baseline) on 2 consecutive days Increase in ICS ≥4 times than the Visit 2 dose Severe exacerbation event


  13. Time to first LOAC event [ Time Frame: Baseline through Week 48 ]

    LOAC events are defined by one or several of the following criteria:

    A 30% or greater reduction from baseline in morning PEF on 2 consecutive days.

    ≥6 additional reliever puffs of short-acting beta-agonists (SABA) OR ≥4 additional puffs of low-dose ICS/formoterol in a 24-hour period (compared to baseline) on 2 consecutive days Increase in ICS ≥4 times than the Visit 2 dose Severe exacerbation event


  14. Change from baseline in the Asthma Daytime Symptom Diary (ADSD) 7-item daily morning score and in the Asthma Nighttime Symptom Diary (ANSD) 7-item daily evening scores at Weeks 2, 4, 8, 12, 24, 36, 48, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, 48, and 60 ]
    ADSD and ANSD have been designed to measure asthma symptoms. Both have overall score from 0- 10 with higher score indicating worse symptom.

  15. Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit during 48 weeks of treatment [ Time Frame: Baseline through Week 48 ]
    Annualized rate of severe asthma exacerbations requiring hospitalization or emergency room or urgent care visit during 48 weeks of treatment.

  16. Change from baseline in the numbers of inhalations/day of SABA or low-dose ICS/formoterol for symptom relief at Weeks 2, 4, 8, 12, 24, 36, 48, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, 48, and 60 ]
    Change from baseline in the numbers of inhalations/day of SABA or low-dose ICS/formoterol for symptom relief at Weeks 2, 4, 8, 12, 24, 36, 48, and 60.

  17. Serum amlitelimab concentrations measured throughout the study [ Time Frame: Baseline thought Week 60 ]
    Serum amlitelimab concentrations measured throughout the study.

  18. Incidence of anti-amlitelimab antibody positive response [ Time Frame: Baseline through Week 60 ]
    Incidence of anti-amlitelimab antibody positive response.

  19. Percentage of participants with treatment-emergent adverse events (TEAEs), including local reactions, AEs of special interest (AESIs), serious adverse events (SAEs) [ Time Frame: Baseline through Week 60 ]
    Percentage of participants with treatment-emergent adverse events (TEAEs), including local reactions, AEs of special interest (AESIs), serious adverse events (SAEs).

  20. Incidence of potentially clinically significant laboratory test, vital signs, and ECG abnormalities in the treatment period [ Time Frame: Baseline through Week 60 ]
    Incidence of potentially clinically significant laboratory test, vital signs, and ECG abnormalities in the treatment period.

  21. Change from baseline in Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ (S)) Self-Administered Score at Weeks 2, 4, 8, 12, 24, 36, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, and 60 ]
    The AQLQ(S) is designed as a self-administered participant reported outcome to measure the functional impairments. The overall score is 1 to 7. Higher AQLQ scores indicate better health-related quality of life.

  22. Change from baseline in St. George's Respiratory Questionnaire (SGRQ) at Weeks 2, 4, 8, 12, 24, 36, 48, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, 48, and 60 ]
    The SGRQ is designed to measure and quantify health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100 where 0 indicates best and 100 indicates worst health.

  23. Proportion of participants with a decrease from baseline of at least 4 points in SGRQ total score at Week 48 [ Time Frame: Week 48 ]
    The SGRQ is designed to measure and quantify health status in adult patients with chronic airflow limitation. A global score ranges from 0 to 100 where 0 indicates best and 100 indicates worst health.

  24. Change from baseline in ACQ-6 score and ACQ-7 at Weeks 2, 4, 8, 12, 24, 36, 48, and 60 [ Time Frame: Baseline to Weeks 2, 4, 8, 12, 24, 36, 48, and 60 ]
    The ACQ-6 is a validated asthma assessment tool that consists of 6 self-assessment questions. The overall scale ranges from 0 = 'totally controlled' to 6 = 'severely unc7ntrolled. The ACQ-7 is a validated asthma assessment tool that consists of 6 self-assessment questions. The overall scale ranges from 0 = 'totally controlled' to 6 = 'severely uncontrolled.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The participant must be between the ages of 18 and 75 inclusive at the time of signing the informed consent.
  • Moderate to severe asthma diagnosed by a physician for ≥ 12 months according to stages 4 and 5 of the Global Initiative for Asthma (GINA ).
  • Participants on existing therapy with medium to high doses of ICS (≥500 μg fluticasone propionate daily or comparable ICS dose in combination with at least one additional controller (e.g., long-acting beta agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], methylxanthines) for at least 3 months.
  • ≥ 1 severe asthma exacerbation in the past year, with at least one exacerbation during treatment with medium to high doses of ICS (≥ 500 μg fluticasone propionate daily or one dose of ICS comparable).
  • Participants with pre-BD forced expiratory volume in 1 second (FEV1) > 40% and < 80% of predicted normal at the screening visit.
  • 5-item ACQ-5 score >1.5 at randomization.
  • Participants with at least 12% reversibility and 200 mL post-BD FEV after administration of albuterol/salbutamol or levalbuterol/levosalbutamol at screening or documented history of a reversibility test.
  • Weight ≥40 kg and ≤150 kg at the randomization visit.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Chronic lung disease other than asthma.
  • Current or former smoker including active vaping of any products and/or marijuana with cessation within 6 months of screening or history of >10 pack-years.
  • Participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic steroids at any time from 1 month prior to screening.
  • Suspicion of, or confirmed, coronavirus disease 2019 (COVID-19) infection during the screening period including known history of COVID-19 infection within 4 weeks prior to Screening; mechanical ventilation or extracorporeal membrane oxygenation (ECMO) secondary to COVID-19 within 3 months prior to Screening; COVID-19 infection who have not yet sufficiently recovered to participate in the procedures of a clinical trial.
  • Active infection or history of clinically significant infection
  • Known history of, or suspected, significant current immunosuppression, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Active or latent tuberculosis (TB)
  • A history of malignancy of any type (excluding basal and squamous cell skin cancer and in situ cervical carcinoma that has been excised and cured >3 years prior to baseline).
  • History of solid organ transplant.
  • Hepatitis B, C or HIV.
  • Pregnant or breastfeeding.
  • History (within last 2 years prior to Baseline) of prescription drug or substance abuse, including alcohol, considered significant by the Investigator.
  • Any prior use of anti-OX40 or anti-OX40L mAb, including amlitelimab.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05421598


Locations
Show Show 123 study locations
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT05421598    
Other Study ID Numbers: DRI17509
U1111-1272-2612 ( Registry Identifier: ICTRP )
2022-000065-41 ( EudraCT Number )
First Posted: June 16, 2022    Key Record Dates
Last Update Posted: December 5, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases